ZS-07
Undisclosed
PreclinicalActive
Key Facts
About Zensun Sci & Tech
Zensun Sci & Tech is a pioneering Chinese biotech with a 20+ year history, dedicated to discovering and developing original, first-in-class medicines. Its lead asset, Neucardin® (recombinant human neuregulin-1), is a novel biologic for heart failure that has received FDA Fast Track designation and is the centerpiece of a pipeline targeting cardiology and oncology. The company successfully raised approximately $76 million in funding, positioning it to advance its clinical programs and expand its global footprint through strategic research collaborations.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |